MDLN
Medline·NASDAQ
--
--(--)
--
--(--)
MDLN fundamentals
During Q4 2025, Medline (MDLN) reported revenue of 7.79B, a YoY change of 14.78%. Net income was 180.00M, a YoY change of -37.72%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q2,2024 | Q3,2024 | Q4,2024 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Mar 31, 2024 | Jun 30, 2024 | Sep 29, 2024 | Mar 30, 2025 | Jun 29, 2025 | Sep 28, 2025 | -- |
End Date | Jun 29, 2024 | Sep 28, 2024 | Dec 31, 2024 | Jun 28, 2025 | Sep 27, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | 6.18B -- | 6.39B -- | 6.78B -- | 6.89B +11.33% | 7.12B +11.38% | 7.79B +14.78% | -- -- |
Sales and Services Revenue | 6.18B -- | 6.39B -- | 6.78B -- | 6.89B +11.33% | 7.12B +11.38% | 7.79B +14.78% | -- -- |
Cost of Revenue | 4.52B -- | 4.63B -- | 4.93B -- | 4.98B +10.13% | 5.24B +13.15% | 5.87B +19.06% | -- -- |
Cost of Goods and Services | 4.52B -- | 4.63B -- | 4.93B -- | 4.98B +10.13% | 5.24B +13.15% | 5.87B +19.06% | -- -- |
Gross Profit | 1.66B -- | 1.76B -- | 1.85B -- | 1.91B +14.62% | 1.88B +6.72% | 1.91B +3.40% | -- -- |
Operating Expenses | 1.15B -- | 1.18B -- | 1.36B -- | 1.26B +10.21% | 1.30B +9.97% | 1.49B +9.57% | -- -- |
Selling, General and Administrative Expenses | 1.14B -- | 1.16B -- | 1.34B -- | 1.25B +9.18% | 1.29B +11.37% | 1.44B +7.46% | -- -- |
Other Operating Expenses | 2.00M -- | 22.00M -- | 18.00M -- | 14.00M +600.00% | 8.00M -63.64% | 48.00M +166.67% | -- -- |
Operating Income | 516.00M -- | 574.00M -- | 492.00M -- | 642.00M +24.42% | 574.00M -- | 425.00M -13.62% | -- -- |
Non-Operating Income (Loss) | -216.00M -- | -236.00M -- | -187.00M -- | -283.00M -31.02% | -229.00M +2.97% | -219.00M -17.11% | -- -- |
Gain (Loss) on Foreign Currency Exchange | -1.00M -- | -22.00M -- | 30.00M -- | -60.00M -5900.00% | -10.00M +54.55% | 5.00M -83.33% | -- -- |
Other Non-Operating Income (Loss) | -2.00M -- | -1.00M -- | -8.00M -- | 0 +100.00% | -6.00M -500.00% | -58.00M -625.00% | -- -- |
Net Interest Expense | 213.00M -- | 213.00M -- | 209.00M -- | 223.00M +4.69% | 213.00M -- | 166.00M -20.57% | -- -- |
Interest Expense | 288.00M -- | 286.00M -- | 272.00M -- | 253.00M -12.15% | 248.00M -13.29% | 200.00M -26.47% | -- -- |
Interest Income | 75.00M -- | 73.00M -- | 63.00M -- | 30.00M -60.00% | 35.00M -52.05% | 34.00M -46.03% | -- -- |
Pretax Income From Continuing Operations | 300.00M -- | 338.00M -- | 305.00M -- | 359.00M +19.67% | 345.00M +2.07% | 206.00M -32.46% | -- -- |
Income Tax Expense | 8.00M -- | 14.00M -- | 16.00M -- | 26.00M +225.00% | 23.00M +64.29% | 26.00M +62.50% | -- -- |
Current Income Tax | -- -- | -- -- | 70.00M -- | -- -- | -- -- | 111.00M +58.57% | -- -- |
Deferred Income Tax | -- -- | -- -- | -24.00M -- | -- -- | -- -- | -20.00M +16.67% | -- -- |
Net Income | 292.00M -- | 324.00M -- | 289.00M -- | 333.00M +14.04% | 322.00M -0.62% | 180.00M -37.72% | -- -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | 0 -- | -- -- | -- -- | -2.00M -- | -- -- |
Net Income Attributable to Owners of the Company | 292.00M -- | 324.00M -- | 289.00M -- | 333.00M +14.04% | 322.00M -0.62% | 182.00M -37.02% | -- -- |
Net Income Attributable to Common Stockholders | 292.00M -- | 324.00M -- | 289.00M -- | 333.00M +14.04% | 322.00M -0.62% | 182.00M -37.02% | -- -- |
Other Comprehensive Income | -50.00M -- | -96.00M -- | -44.00M -- | 55.00M +210.00% | -10.00M +89.58% | -9.00M +79.55% | -- -- |
Total Comprehensive Income | 242.00M -- | 228.00M -- | 245.00M -- | 388.00M +60.33% | 312.00M +36.84% | 171.00M -30.20% | -- -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | 0 -- | -- -- | -- -- | -2.00M -- | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | 242.00M -- | 228.00M -- | 245.00M -- | 388.00M +60.33% | 312.00M +36.84% | 173.00M -29.39% | -- -- |
Basic EPS | -- -- | -- -- | -- -- | -- -- | -- -- | 0.14 -- | -- -- |
You can ask Aime
What guidance did Medline's management provide for the next earnings period?What factors drove the changes in Medline's revenue and profit?Did Medline beat or miss consensus estimates last quarter?What is Medline's latest dividend and current dividend yield?What does Medline do and what are its main business segments?What is the revenue and EPS growth rate for Medline year over year?What were the key takeaways from Medline’s earnings call?What were the key takeaways from Medline's earnings call?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
